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background
 
Encasing bedding in impermeable covers reduces exposure to house-dust mites, but the
clinical benefit of this intervention as part of mite-avoidance measures for patients
with allergic rhinitis is not known. We performed a multicenter, randomized, placebo-
controlled trial of one year of use of impermeable bedding covers in the bedrooms of
patients with rhinitis who were sensitized to house-dust mites to determine the effects
on the signs and symptoms of disease.
 
methods
 
Three participating university medical centers enrolled 279 patients with allergic rhini-
tis who were randomly assigned to receive impermeable or non-impermeable (control)
covers for their mattress, pillow, and duvet or blanket. At the start of the study, all par-
ticipants received information on general allergen-avoidance measures. The severity of
rhinitis was measured on a rhinitis-specific visual-analogue scale and by means of a daily
symptom score and nasal allergen provocation testing. We also measured the concen-
trations of 
 
Dermatophagoides pteronyssinus
 
 (Der p1) and 
 
D. farinae
 
 (Der f1) in dust from
patients’ mattresses, bedroom floors, and living-room floors at base line and after 12
months as a measure of the efficacy of the intervention.
 
results
 
A total of 232 patients completed the study. There was a significant reduction in Der p1
and Der f1 concentrations in the mattresses of the impermeable-cover group, whereas
there was no significant reduction in the control group. However, there was no signif-
icant effect on the clinical outcome measures. Analyses of subgroups defined according
to age, level of exposure, type and severity of sensitization, or characteristics of the pa-
tient’s home had similar results.
 
conclusions
 
Mite-proof bedding covers, as part of a structured allergy-control program, reduced the
level of exposure to mite allergens. Despite the success of the intervention, this single
avoidance measure did not lead to a significant improvement of clinical symptoms in
patients with allergic rhinitis.
abstract
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llergic rhinitis is the most prev-
 
alent of allergic diseases, affecting 20 mil-
lion to 40 million people in the United
States alone. Approximately $1.2 billion is spent in
the United States annually on medications or pre-
ventive measures for allergic rhinitis.
 
1
 
 Several con-
sensus reports stress the importance of environ-
mental control aiming at the reduction of exposure
to house-dust mites among patients with allergic
rhinitis.
 
2,3
 
 Surprisingly, there is little evidence that
such interventions have a beneficial effect on the
symptoms of rhinitis. In a recent Cochrane review,
Sheikh and Hurwitz selected four trials that fulfilled
the criteria for randomized clinical trials, all involv-
ing patients with allergic rhinitis.
 
4
 
 The studies that
were included were considered to be small and of
poor quality. Only one uncontrolled study had inves-
tigated the effects of bedroom-based allergen-avoid-
ance measures, including the use of covers wrap-
ping the mattress.
 
5
 
 On the basis of early reports of
the effectiveness of these covers when used by pa-
tients with asthma,
 
6-8
 
 this intervention has been put
forward in U.S.
 
9
 
 and European
 
2,3,10
 
 guidelines as
the first and most effective allergy-control measure
that can be taken by patients. The use of covers to
encase bedding has been proposed as an essential
action, whereas the removal of carpets and the min-
imization of the amount of upholstered furniture
have been described as desirable actions.
 
11
 
Environmental control, however, represents a
financial burden for both patients and society. In
the Netherlands, financial reimbursement for bed-
ding covers can be obtained from health insurance
companies. Yearly compensation was estimated at
$2.4 million in 2001 (Holwerda BMP, Dutch Health
Insurance Board: personal communication). At the
same rate of reimbursement, about $42 million
would be spent on such covers in the United States.
A recent U.S. position paper urges insurers and oth-
er third-party payers to cover the costs of imperme-
able covers for mattresses, comforters, and pillows,
as well as other proven therapies designed to reduce
exposure to allergens.
 
9
 
 In the Netherlands, insurers
already offer financial compensation for the pur-
chase of bedding covers. The financial implication
of such a policy or recommendation necessitates
rigorous studies to assess the effectiveness of imper-
meable covers as a part of allergy-control measures
in daily practice. We conducted a large multicenter
trial to examine the clinical effects of mite-proof
covers for the bedding of mite-sensitive patients on
the symptoms and signs of allergic rhinitis.
 
study setting and patients
 
The study was part of a larger trial involving patients
with allergic rhinitis, asthma, atopic dermatitis, or
some combination of these conditions (the Dutch
Mite Avoidance Study). The setting and study design
have been described elsewhere.
 
12
 
 Potentially eligi-
ble patients had to meet our definition of house-
dust-mite sensitization
 
3
 
; our use of patients from
the larger study allowed us to select patients with
allergic asthma or atopic dermatitis, provided that
they also had a diagnosis of rhinitis. All study pa-
tients were required to have one or more symptoms;
nasal obstruction was present in 86 percent of
the patients, watery nasal discharge in 82 percent,
sneezing in 94 percent, and nasal itching in 78 per-
cent. Of the patients who were included, 95 percent
had nasal symptoms arising from exposure to dust
in the home. Other nasal diseases and nasal deform-
ities were ruled out with the use of rhinoscopy.
Skin tests and measurement of specific IgE were
used to establish sensitization to mite allergen.
Since it may be difficult to diagnose perennial aller-
gic rhinitis, we also required patients to have a posi-
tive nasal allergen-challenge test as an additional
diagnostic criterion. With this test, we prove that
nasal exposure to mite allergen elicits symptoms
in a dose-dependent manner.
 
13
 
 Other criteria for in-
clusion and exclusion are shown in Table 1. Among
the 325 eligible patients entering the Dutch Mite
Avoidance Study, the group with rhinitis was by far
the largest (279 patients). The study protocol was
approved by the medical ethics committees of all
three participating university hospitals, and all pa-
tients gave written informed consent.
 
study design and blinding
 
The study was designed as a randomized, double-
blind, placebo-controlled trial. At base line, eligible
patients were randomly assigned to receive either
covers for bedding that were not impermeable to
mite allergen (control covers) or impermeable bed-
ding covers; assignments were made at the Julius
Center with the use of a central computerized ran-
domization schedule. The control covers used in the
study had an unloaded pore size of 0.1¬0.08 mm;
the application of a force of 200 N changed the pore
size to 0.1¬0.1 mm. The control covers provided
a 15 percent barrier against allergen (allowing 85
percent of allergen to pass through), as compared
with the 98 percent barrier provided by the imper-
a methods
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meable covers. After randomization, the patient’s
initials and date of birth and the measurements of
his or her pillows, duvets, and mattress were faxed
to the Julius Center. Each patient was assigned a re-
search number. The research number and the bed-
ding measurements were sent by the Julius Center
to the manufacturer of the covers (Haarlem Aller-
gen Laboratories). A cardboard box containing all
covers was sent to the research center, with the re-
search number written on the box. Each patient
took his or her box home and opened it in the ab-
sence of research staff. Covers were put on pil-
lows, duvets, and mattresses after base-line dust
collection. Dust sampling was performed by trained
students who did not participate in the obtaining of
clinical measurements, in order to ensure blinding.
The use of covers was part of a protocol-driven
allergy-control program in which participants were
encouraged to wash and clean the bedding weekly
in water that was 60°C and to clean, heat, and ven-
tilate their homes according to a regular schedule,
as outlined in the guidelines of the Netherlands
Asthma Foundation (which, in turn, are based on
international guidelines
 
9,10
 
). In addition, we urged
patients not to replace duvets, blankets, or mattress-
es and not to change floor surfaces, upholstered fur-
niture, or carpets after the start of the trial.
 
clinical measurements
 
All clinical measurements at base line and after 12
months of treatment were obtained between Sep-
tember and December, the peak season for house-
dust mites in the Netherlands. Study patients with
an allergy to pollen were seen in October or Novem-
ber, at least one month after the end of the pollen
season. All antihistamine use was discontinued at
least three days before clinical measurements and
all nasal-spray use was discontinued two to four
weeks before clinical measurements, so that the re-
sults of nasal allergen-provocation testing would
not be influenced by treatments. Before the covers
were put on the bedding, patients visited the research
center on two consecutive days, when they filled
in visual-analogue scales and quality-of-life ques-
tionnaires and underwent a nasal allergen-provo-
cation test, skin tests, and lung-function tests (de-
scribed below). For 14 days before these base-line
visits, patients recorded a daily symptom score (de-
scribed below). The patients put the covers on their
bedding in their bedrooms after dust samples had
been collected. For each patient, the presence or ab-
sence of coexisting allergic asthma and atopic der-
matitis was assessed according to preset criteria.
 
12
 
primary end point
 
The primary end point was the score on the rhini-
tis-specific visual-analogue scale, which measures
the severity of the disease as experienced by the pa-
tient. Scores range from 0 (no symptoms) to 100
(very severe symptoms). In previous studies, visual-
analogue scales have been demonstrated to be sen-
sitive and reliable outcome measures.
 
16-19
 
secondary end points
 
Secondary end points included the daily symptom
score, the score on nasal allergen-provocation test-
ing, and concentrations of 
 
Dermatophagoides pteronys-
sinus
 
 (Der p1) and 
 
D. farinae
 
 (Der f1) in dust samples
from the patient’s mattress, bedroom floor, and liv-
ing-room floor. For the daily symptom score, pa-
tients recorded symptoms on a daily symptom card
for 14 consecutive days before their first screening.
In this symptom diary, they noted occurrences of na-
sal obstruction, nasal discharge, and nasal itching.
The severity of symptoms was scored on a four-point
scale (with a score of 0 denoting no symptoms at all
and a score of 3 denoting very serious symptoms).
The average score for an item was calculated if a
score for that item was recorded on at least 12 of the
14 days. The daily symptom score, which has been
proved to reflect the response to treatment in many
randomized clinical trials,
 
17,20,21
 
 was calculated as
the average of the mean scores for the three items.
Nasal allergen-provocation tests were included
for purposes of diagnosis, and the score on these
tests was included as a secondary end point.
 
22
 
 As
previously described,
 
23
 
 the response to nasal chal-
 
* Radioallergosorbent test (RAST) class 2 is defined by an anti–house-dust-mite 
IgE level of 0.7 to 3.5 kU per liter. The skin-test index is the quotient of the di-
ameter of the allergen-induced wheal divided by the diameter of the hista-
 
mine-induced wheal, determined according to a validated protocol.
 
14,15
 
Table 1. Criteria for Inclusion and Exclusion.*
Criteria for Inclusion Criteria for Exclusion
 
An age of 8–50 yr
Patient not pregnant or lactating
No bedding covers in place or patient 
willing to remove them for the 
duration of the study
Clinical history of allergic rhinitis and a 
positive nasal allergen-provocation 
test with house-dust-mite allergen
RAST class ≥2, skin-test index ≥0.7 
for house-dust mite, or both
≥0.2 µg of Der p1 or Der f1 per gram of 
dust in sample from mattress
Pets at home and a positive skin test
(index ≥0.7), RAST class ≥2, or
both for the pet allergen
Daily use of inhaled corticosteroids
≥1600 µg/day (in adults) or 
≥800 µg/day (in children)
Daily use of oral corticosteroids
Daily use of cyclosporine
Regular use of antibiotics for upper
or lower airway infection
Regular use of oral corticosteroids
for exacerbations of asthma
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lenge with house-dust-mite extract in doses of 100,
1000, and 10,000 biologic units per milliliter was as-
sessed with the use of a symptom score with a range
of 0 to 12 points, with a maximum of 36 points.
 
24
 
The vacuuming procedures for the collection,
extraction, and analysis of dust samples at base line
and after 12 months have been described exten-
sively elsewhere.
 
25
 
 Mattress dust was collected with
the bottom sheet still on the mattress. In addition,
dust samples were obtained from the bedroom and
living-room floors. The concentration of Der p1 was
measured relative to the World Health Organiza-
tion reference values by competitive radioimmuno-
assay
 
26
 
; the results in nanograms per international
unit (IU) were converted to micrograms per gram
of dust with the use of 0.125 as the conversion fac-
tor. The concentration of Der f1 was measured by
monoclonal enzyme-linked immunosorbent assay
(Indoor Biotechnologies).
 
statistical analysis
 
Before the conduct of the study, we estimated that
we needed at least 44 patients in each group, on the
assumption that a clinically relevant reduction of
25 percent from a mean (
 
±
 
SD) score on the visual-
analogue scale of 54
 
±
 
27 points
 
27
 
 could be detected
with a power of 90 percent and a two-tailed alpha
level of 0.05.
 
Figure 1. Disposition of the Patients.
279 Patients randomized
140 In control group 139 In impermeable-cover group
121 Eligible for analysis 115 Eligible for analysis
24 Withdrawn after 12 mo
Pregnant (2)
Moved (7)
Protocol violation (5)
Illness (3)
Missed medication too
often (1)
Study took too much time (1)
Study was too bothersome (2)
Covers were too hot (2)
Lack of cooperation (1)
19 Withdrawn before 12 mo
Pregnant (2)
Moved (4)
Protocol violation (2)
Study took too much time (1)
Lost contact (1)
Study was too bothersome (1)
Covers were too hot (1)
Unable to stop nasal
medication (1)
Unknown(3)
No reason given (3)
No data on the primary outcome
for 3 patients
No data on the primary outcome
for 1 patient
118 With complete data on the 
primary outcome
114 With complete data on the 
primary outcome
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Log transformation was performed for the sum
of the Der p1 and Der f1 concentrations, the total
and specific IgE concentrations, and the eosinophil
count. Intention-to-treat analysis was performed
with the use of data on all 232 patients from whom
valid scores on the visual-analogue scale could be
obtained after 12 months. Effectiveness was esti-
mated with the use of unpaired t-tests to assess the
mean difference between groups (or the mean ratio,
for log-transformed variables) in changes from base
line in the scores on the visual-analogue scale and
in the secondary end points and their correspond-
ing 95 percent confidence intervals.
In subgroup analyses, we examined potential ef-
fect modification with regard to scores on the visu-
al-analogue scale by sensitization to other allergens
(weed pollen, cat allergen, or dog allergen), charac-
teristics of the inside of the patient’s home (smooth
surfaces vs. other types of surfaces), degree of sen-
sitivity to house-dust-mite allergen (a radioaller-
gosorbent test [RAST] class of 4, 5, or 6 vs. a RAST
class of less than 4, representing anti–house-dust-
mite IgE levels above 17.5 kU per liter and levels of
17.5 kU per liter or below, respectively) and the con-
centration of Der p1 and Der f1 (≥5 µg vs. <5 µg of
Der p1 and Der f1 per gram of dust).
After 12 months, the geometric mean concentration
of Der p1 and Der f1 in the mattress samples was
significantly lower in the impermeable-cover group.
The ratio of the level 12 months after the covers were
put on to the level before the covers were put on was
0.31 in the impermeable-cover group (95 percent
confidence interval, 0.21 to 0.46), as compared with
a ratio of 0.82 in the control group (95 percent con-
fidence interval, 0.58 to 1.15). The reductions from
base line to 12 months in the concentration of Der
p1 and Der f1 in bedroom-floor dust were not sta-
tistically significant in the control group (mean ratio
of the level at 12 months to the level at the begin-
ning of the study, 0.83; P=0.49), whereas there was
a statistically significant reduction in the group us-
ing impermeable covers (mean ratio, 0.69; P=0.04).
However, the intervention was not found to have
a significant effect (P=0.44 by unpaired t-test).
A somewhat larger, statistically significant reduc-
tion was found for the concentration in living-
room-floor dust in the control group (mean ratio
of the 12-month level to the beginning level, 0.67;
P=0.01 by paired t-test, as compared with a ratio of
0.90 [P=0.49] in the impermeable-cover group).
Again, the intervention was not found to have a sig-
nificant effect (P=0.21 by unpaired t-test).
The disposition of patients in the trial is shown
in Figure 1. The base-line clinical characteristics
were similar in the control group and the imper-
meable-cover group (Table 2). Patients in both
groups had a significant decrease in the mean score
on the visual-analogue scale (P<0.001 for both
changes). A small decrease in the daily symptom
results
 
* Plus–minus values are means ±SE; values for eosinophil count, total IgE con-
centration, house-dust-mite–specific IgE concentration, and Der p1 and Der f1 
concentration are geometric means with 95 percent confidence intervals. 
The skin-test index is the quotient of the diameter of the allergen-induced 
wheal divided by the diameter of the histamine-induced wheal; scores on the 
rhinitis-specific visual-analogue scale range from 0 to 100, with higher scores 
indicating greater severity of symptoms; scores on the nasal allergen-provoca-
tion test range from 0 to 36, with higher scores indicating more severe symp-
toms on exposure to house-dust-mite allergen; and daily symptom scores 
range from 0 to 3, with higher scores indicating greater severity of symptoms. 
 
None of the differences between the groups were statistically significant.
 
Table 2. Base-Line Characteristics of the 232 Patients Who Completed 
the Study.*
Characteristic
Impermeable-
Cover Group
(N=114)
Control Group
(N=118)
 
Age (yr) 25.7±1.1 26.9±1.1
Male sex (%) 38.6 42.4
Smoking (%) 13.2 10.2
Asthma (%) 46.5 48.3
Dermatitis (%) 26.3 23.7
Cosensitization
Grass pollen (%) 57.0 54.3
Tree pollen (%) 40.4 37.1
Weed pollen (%) 19.3 17.2
Cat allergen (%) 54.0 48.3
Dog allergen (%) 59.6 57.8
Eosinophil count (per mm
 
3
 
) 281  (237–333) 291  (250–338)
Total IgE concentration (kU/liter) 232  (176–305) 228  (176–295)
House-dust-mite–specific IgE 
concentration (kU/liter)
12.7  (9.5–17.0) 13.3  (10.3–17.2)
Skin-test index for house-dust mites
(biologic units)
0.91±0.64 0.98±0.64
Score on the rhinitis-specific visual-
analogue scale
52.18±2.89 49.82±2.76
Nasal allergen-provocation test score 18.49±0.54 18.14±0.57
Daily symptom score 2.22±0.14 2.22±0.15
Concentration of Der p1 and Der f1 
in the mattress (µg/g of dust)
4.69 (3.45–6.38) 5.28 (3.75–7.43)
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* Plus–minus values are means ±SE unless otherwise indicated. Scores on the rhinitis-specific visual-analogue scale range 
from 0 to 100, with higher scores indicating greater severity of symptoms; scores on the nasal allergen-provocation test 
range from 0 to 36, with higher scores indicating more severe symptoms on exposure to house-dust-mite allergen; and 
daily symptom scores range from 0 to 3, with higher scores indicating greater severity of symptoms. CI denotes confi-
dence interval.
† Values are geometric means with 95 percent confidence inervals.
‡ Data are the ratios of the concentration at 12 months to the concentration at base line.
 
§ Value is the ratio of the mean change in the impermeable-cover group to the mean change in the control group.
 
Table 3. Clinical Effects of Impermeable Covers in the Bedrooms of 232 Patients with Allergic Rhinitis.*
Variable Impermeable-Cover Group Control Group P Value
Primary end point
 
Rhinitis-specific visual-analogue scale
No. of patients 114 118
Base-line score 52.18±2.89 49.82±2.76 0.56
12-Mo score 42.35±2.79 38.96±2.68 0.38
Mean change (95% CI) –9.83 (–15.28 to –4.39) –10.86 (–16.64 to –5.09)
P value <0.001 <0.001
Difference between changes (95% CI) 1.03 (–6.87 to 8.94) 0.80
 
Secondary end points
 
Nasal allergen-provocation test
No. of patients 112 114
Base-line score 18.49±0.55 17.92±0.57 0.47
12-Mo score 18.26±0.60 17.59±0.60 0.43
Mean change (95% CI) –0.23 (–1.28 to 0.81) –0.33 (–1.42 to 0.76)
P value 0.66 0.55
Difference between changes (95% CI) 0.10 (–1.40 to 1.60) 0.90
Daily symptom score
No. of patients 100 98
Base-line score 2.25±0.15 2.23±0.16 0.93
12-Mo score 2.07±0.16 1.91±0.17 0.47
Mean change (95% CI) –0.18 (–0.45 to 0.1) –0.33 (–0.63 to ¡0.02)
P value 0.20 0.04
Difference between changes (95% CI) 0.15 (–0.26 to 0.56) 0.48
Der p1 and Der f1 in mattress (µg/g of dust)
No. of patients 79 87
Base-line concentration† 4.12 (2.93–5.79) 5.91 (4.00–8.73) 0.18
12-Mo concentration† 1.29 (0.95–1.75) 4.84 (3.62–6.47) <0.001
Mean change (95% CI)‡ 0.31 (0.21 to 0.46) 0.82 (0.58 to 1.15)
P value <0.001 0.25
Difference between changes (95% CI)§ 0.38 (0.23 to 0.64) <0.001
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score was seen in the control group. However, there
was no significant difference between groups in the
score on the visual-analogue scale, the nasal aller-
gen-provocation score, or the daily symptom score
(Table 3). A subgroup of 74 patients (31.9 percent)
were not sensitized to weed pollen, cat allergen, or
dog allergen, whereas 100 patients (43.1 percent)
had smooth floor surfaces in their bedroom and
living room and no rugs in the bedroom.
On multivariate regression analysis, including
the intervention as the main determinant, as well
as age, smoking status, sex, cosensitization to oth-
er allergens, characteristics of the interior of the pa-
tient’s home, and terms for the interactions be-
tween these factors and the intervention, we found
no statistically significant modification of the ef-
fect of the intervention by any of these characteris-
tics. Subgroup analyses showed that sensitization
to house-dust-mite allergen alone or to multiple
allergens, characteristics of the interior of the pa-
tient’s home, and the level of exposure to Der p1 and
Der f1 did not influence the effect of the interven-
tion on the primary outcome measure (Table 4). We
did not find greater improvement in the scores on
the visual-analogue scale in the impermeable-cover
group than in the control group, either among 157
patients with high sensitivity to dust-mite allergen
(mean in the impermeable-cover group minus the
mean in the control group, 1.32 [95 percent confi-
dence interval, –8.70 to 11.35]; P=0.79) or among
75 patients with low sensitivity to dust-mite aller-
gen (mean in the impermeable-cover group minus
the mean in the control group, –5.40 [95 percent
confidence interval, –18.22 to 7.43]; P=0.40).
Our randomized, controlled trial involving patients
with allergic rhinitis demonstrated a lack of clini-
cal effect of mite-proof covers for mattresses, pil-
lows, and duvets on signs and symptoms of rhini-
tis. No clinical effect was seen despite a significant
reduction (by a factor of 2.6) in the level of exposure
to house-dust mites in the mattress. A similar lack
of effect of mattress encasings in the much smaller
subgroups of patients from the Dutch Mite Avoid-
ance Study who had atopic dermatitis
 
25
 
 or asthma
were in line with our overall results. Furthermore,
our findings are in accordance with a recently up-
dated meta-analysis of 29 trials involving 939 pa-
tients with asthma showing that physical methods
(in 15 trials), chemical methods (in 9 trials), or a
combination of methods (in 5 trials) did not result
in the improvement of symptoms of asthma.
 
28
 
There are limitations to this study. Although 279
patients were included in the study, we were able to
examine only 232 patients at the end of the study.
The dropout rate did not appear to vary according
to the presence or absence of known risk factors.
Adjustment for known differences between the two
groups did not change the direction or magnitude
of the results. Furthermore, the study population
was heterogeneous — that is, patients were recruit-
ed from tertiary referral departments, general hos-
pitals, and general practices and by advertisements.
Moreover, patients with asthma or atopic dermati-
tis were also eligible for inclusion in the Dutch Mite
Avoidance Study,
 
25
 
 so the prevalence of these coex-
isting conditions and the mean IgE values were high
among the study patients. The advantage of the re-
cruitment process is that the study population is
representative of all patients with rhinitis seen in
clinical practice for whom bedding covers are rec-
ommended by consensus statements. The disad-
vantage is that very selected groups of patients who
might benefit from the intervention could not be
identified. However, in the subgroups that could be
analyzed, we were not able to identify such a group
of patients.
Possibly, the base-line level of Der p1 and Der f1
was too low, and consequently, the reduction in al-
lergen exposure could only be moderate. Other stud-
ies have demonstrated much larger reductions in
the concentration of Der p1.
 
29,30
 
 The base-line
levels we observed, however, were in line with the
results of the large-scale Dutch Prevention and In-
cidence of Asthma and Mite Allergy study that in-
volved 810 very young children.
 
31
 
 Apparently, either
patients who were sensitized to house-dust mites
had already applied some measures to lower house-
dust-mite levels before entering the trial or the living
conditions were unfavorable to the growth of house-
dust mites. Subgroup analysis of patients with a
high level of exposure did not reveal any clinical ef-
fect from impermeable covers. Therefore, the level
of exposure seems not to be a major constraint in
our study.
Our results do not preclude possible effective-
ness of environmental control measures in gener-
al. Our objective was to establish the specific and
isolated effect of covers for mattresses, duvets, and
pillows in patients with allergic rhinitis who are al-
lergic to house-dust-mite allergen. Other sources of
house-dust-mite allergen are the bedroom and liv-
discussion
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 Since reductions
from base line in the concentration of Der p1 and
Der f1 in samples from the bedroom and living-
room floors were either small or absent, the use of
covers cannot control allergen from these sources.
With respect to other allergens, allergy to mold is
uncommon in the Netherlands,
 
34
 
 and cockroach
infestation was not observed during the visits to pa-
tients’ homes. Moreover, in the Netherlands, no data
are available suggesting that cockroach allergen is
an important cause of allergy. Sensitization to oth-
er allergens that were not controlled for in this study
may have masked potential benefits from covers,
but data from the subgroup analysis do not sup-
 
Table 4. Mean Scores and Changes in Scores on the Rhinitis-Specific Visual-Analogue Scale.*
Variable Impermeable-Cover Group Control Group P Value
 
Patients not sensitized to other allergens
No. of patients 35 39
Base-line score 54.86±5.09 47.33±4.56 0.27
12-Mo score 43.91±5.15 38.33±4.58 0.42
Mean change (95% CI) –10.94 (–19.38 to –2.50) –9.00 (–19.68 to 1.68)
P value 0.13 0.10
Difference between changes (95% CI) –1.94 (–15.54 to 11.65) 0.29
Patients sensitized to other allergens
No. of patients 79 79
Base-line score 51.00±3.52 51.05±3.47 0.99
12-Mo score 41.66±3.33 39.27±3.32 0.80
Mean change (95% CI) –9.34 (–16.37 to –2.32) –11.78 (–18.77 to –4.80)
P value 0.01 0.001
Difference between changes (95% CI) 2.44 (–7.39 to 12.27) 0.77
Patients with wall-to-wall carpets or rugs in 
bedroom, living room, or both
No. of patients 64 68
Base-line score 53.88±3.70 51.59±3.69 0.66
12-Mo score 41.91±3.67 41.41±3.82 0.93
Mean change (95% CI) –11.97 (–19.39 to –4.55) –10.18 (–17.00 to –3.35)
P value 0.002 0.004
Difference between changes (95% CI) –1.79 (–11.76 to 8.19) 0.72
Patients with smooth floor surfaces and no rugs
in the bedroom
No. of patients 50 50
Base-line score 50.02±4.60 47.42±4.20 0.68
12-Mo score 42.92±4.31 35.60±3.59 0.20
Mean change (95% CI) –7.10 (–15.33 to 1.13) –11.80 (–22.06 to 1.54)
P value 0.09 0.02
Difference between changes (95% CI) 4.70 (–8.30 to 17.70) 0.48
Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at ERASMUS UNIVERSITEIT MEDISCH BIBLIO on November 8, 2006 . 
 n engl j med 
 
349;3
 
www.nejm.org july 
 
17, 2003
 
evaluation of bedding covers in rhinitis
 
245
 
port this possibility. In conclusion, our study does
not lend support to a possible benefit of covers in
the bedroom as part of measures for allergy control
in patients with allergic rhinitis who are allergic to
house-dust-mite allergen, in spite of a significant
reduction in house-dust-mite exposure.
 
Supported by the Netherlands Organization for Health Research
and Development.
 
* Plus–minus values are means ±SE, unless otherwise indicated. There was no significant difference in the base-line score 
on the visual-analogue scale between the subgroups defined according to the concentration of Der p1 and Der f1 in mat-
tress dust. Scores on the visual-analogue scale range from 0 to 100, with higher scores indicating greater severity of ill-
ness. CI denotes confidence interval.
† The geometric mean concentration in this subgroup was 19.10 µg per gram of dust.
 
‡ The geometric mean concentration in this subgroup was 1.39 µg per gram of dust.
 
Table 4. (Continued.)
Variable Impermeable-Cover Group Control Group P Value
 
Children (8–17 yr of age)
No. of patients 38 40
Base-line score 56.84±5.08 46.45±5.10 0.15
12-Mo score 50.44±5.03 40.27±4.71 0.14
Mean change (95% CI) –6.40 (–16.39 to 3.64) –6.18 (–17.58 to 5.23)
P value 0.20 0.28
Difference between changes (95% CI) –0.22 (–14.79 to 15.23) 0.97
Adults (18–50 yr of age)
No. of patients 76 78
Base-line score 49.86±3.51 51.55±3.27 0.72
12-Mo score 38.30±3.26 38.28±3.27 1.0
Mean change (95% CI) –11.56 (–18.13 to –4.97) –13.27 (–19.89 to –6.65)
P value 0.01 <0.001
Difference between changes (95% CI) 1.71 (–7.54 to 10.98) 0.72
Patients with a mattress Der p1 and Der f1 
concentration ≥5 µg/g of dust†
No. of patients 54 49
Base-line score 53.92±4.11 53.45±4.39 0.93
12-Mo score 45.14±4.29 45.10±4.29 1.00
Mean change (95% CI) –8.78 (–17.04 to –0.51) –8.35 (–17.70 to 1.09)
P value 0.04 0.08
Difference between changes (95% CI) –0.43 (–12.83 to 11.78) 0.94
Patients with a mattress Der p1 and Der f1 
concentration <5 µg/g of dust‡
No. of patients 50 55
Base-line score 49.64±4.57 44.07±3.98 0.36
12-Mo score 38.74±4.11 32.32±3.53 0.24
Mean change (95% CI) –10.90 (–19.31 to –2.49) –11.75 (–20.23 to –3.26)
P value 0.01 0.08
Difference between changes (95% CI) 0.85 (–10.99 to 12.68) 0.89
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